Igm Biosciences, Inc. Stock Price, News & Analysis

IGM Biosciences announced promising Phase 1 data for IGM-8444 in metastatic colorectal cancer, demonstrating an encouraging safety profile when combined with FOLFIRI chemotherapy. The trial revealed multiple confirmed patient responses, with some patients achieving substantial tumor shrinkage. Median progression-free survival was reported at 5.5 months for certain patient cohorts. Following these results, a randomized trial in second-line patients is set to begin in Q1 2023, aiming to further evaluate the effectiveness of IGM-8444 alongside FOLFIRI and bevacizumab.

IGM Biosciences, a clinical-stage biotechnology company, announced that CEO Fred Schwarzer will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 5:15 p.m. PST in San Francisco. The event will be available via a live webcast on the company's website, with a replay accessible for 30 days.

The company focuses on developing IgM antibodies for treating cancer, infectious diseases, and autoimmune disorders, leveraging a collaboration with Sanofi to develop IgM antibody agonists.

IGM Biosciences presented promising preclinical data for IGM-2644 and IGM-2537 at the 2022 ASH Annual Meeting. Both bispecific IgM antibodies showed potential anti-tumor activity with favorable safety profiles. IGM-2644 demonstrated superior cytotoxicity against myeloma cells compared to traditional IgG antibodies and is set for a Phase 1 trial in early 2023. Similarly, IGM-2537 displayed potent activity against acute myeloid leukemia with minimal cytokine release, with IND filing anticipated in 2023. Biomarker data for imvotamab also indicated efficacy in low CD20 expressing tumors.

IGM Biosciences, a clinical-stage biotechnology company focused on IgM antibodies, announced that CEO Fred Schwarzer will participate in a virtual fireside chat at the Bank of America Biotech SMID Cap Conference on December 8, 2022, at 2:45 p.m. EST.

The event will be webcast live on the company’s website, with a replay available for 90 days. IGM is dedicated to developing innovative therapies for cancer and other diseases, leveraging its IgM antibody technology, which offers superior binding capabilities compared to traditional antibodies.

IGM Biosciences, a clinical-stage biotechnology firm focusing on IgM antibodies, announced that CEO Fred Schwarzer will participate in several investor conferences. The events include:

• Stifel Healthcare Conference on November 15 in New York
• Jefferies London Healthcare Conference on November 17 in London
• Evercore ISI HealthCONx Conference on December 1 (virtual)

Live webcasts will be available on the Company’s website and will remain archived for 90 days post-event.

IGM Biosciences (Nasdaq: IGMS) reported its Q3 2022 financial results, showing a net loss of $58 million, unchanged at $1.32 per share. Cash and investments rose to $469.1 million compared to $229.5 million at the end of 2021. Collaboration revenue reached $0.3 million, up from zero in Q3 2021. The company is progressing in its T cell engager portfolio, with promising data from the Phase 1 trial of imvotamab, where 7 of 8 complete response patients remain tumor-free after a year. IGM aims for a Phase 2 update on imvotamab in Q1 2023.

IGM Biosciences and ADC Therapeutics have partnered to evaluate a combination therapy for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). Their collaboration focuses on IGM's bispecific antibody, imvotamab, combined with ADC's ZYNLONTA^®. A Phase 1 trial is expected to start in Q1 2023. Preliminary data shows imvotamab achieved a 50% complete response rate in prior studies, with manageable safety profile.

IGM Biosciences and ADC Therapeutics have formed a clinical trial collaboration to examine a combination therapy for relapsed/refractory B cell non-Hodgkin’s lymphoma (NHL). This partnership will evaluate IGM’s imvotamab, a bispecific antibody, alongside ADC’s ZYNLONTA^®, an antibody-drug conjugate. The Phase 1 trial is slated to commence in Q1 2023. Previous data indicated a 50% complete response rate for imvotamab at optimal dosing, with manageable safety profiles. Both companies aim to address significant unmet medical needs in lymphoma treatments.

IGM Biosciences, a clinical-stage biotechnology company focused on IgM antibodies, has announced that CEO Fred Schwarzer will speak at three major investor conferences in New York. The conferences include the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, Baird 2022 Global Healthcare Conference on September 13, and H.C. Wainwright 24th Annual Global Investment Conference on September 14. Live webcasts will be available on the company's website, with replays archived for 90 days.